#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Obesity Activated PI3 kinase delta syndrome Lymphangioma Neurotrophic keratopathy Anti-myelin-associated glycoprotein antibodies positive Congenital growth hormone deficiency Non-small cell lung cancer metastatic Kearns-Sayre syndrome Chronic graft versus host disease in intestine Malignant fibrous histiocytoma Hereditary spastic paraplegia Raynaud's phenomenon Waldenstrom's macroglobulinaemia Philadelphia positive acute lymphocytic leukaemia Idiopathic pulmonary fibrosis More trials…

    Learn about Rare Diseases

    Hairy cell leukaemia recurrent – Treatment Small intestine leiomyosarcoma – Basic Information Haemophilia B without inhibitors Inclusion body myositis Congenital generalised lipodystrophy – Diagnostics Mantle cell lymphoma refractory Encephalitis autoimmune – Life with Disease Cytokine release syndrome – Life with Disease Familial amyotrophic lateral sclerosis – Treatment Medulloblastoma recurrent More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sitagliptin Tislelizumab Febuxostat Betamethasone Keto-Isoleucine Calcium Deucrictibant A3907 Macrogol 4000 ULTEVURSEN Azd8421 Levosimendan Daxdilimab SOFTISAN 378 Gadoquatrane VOROLANIB Aluminium Oxide, Hydrated Gsk4527226 Nvl-655 Mometasone Furoate Ph. Eur. Sodium Thiosulfate More therapies…

    Learn about Your Condition

    Hypoglycaemia Short-bowel syndrome Lip and/or oral cavity cancer Genital infection female Epilepsy Neuroendocrine tumour Undifferentiated sarcoma Triple negative breast cancer BK virus infection Inborn error of metabolism Infantile spasms Lichenoid keratosis Drug eruption Pancreatic failure Vasoplegia syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn’s disease or ulcerative colitis

    Not recruiting

    2 1
    Austria Belgium Bulgaria Croatia Czechia France +8

  • Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Not recruiting

    4 1 1 1
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia France Germany +7

  • Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Nemtabrutinib
    • Zilovertamab Vedotin
    Czechia Estonia Germany Ireland Italy Poland +3

  • A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Enzalutamide
    Belgium Bulgaria Czechia Finland France Germany +6

  • Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • 2-Amino-6-Fluoro-N-(5-Fluoro-4-(1-Methyl-1H-Imidazol-5-Yl)Pyridin-3-Yl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide
    • 8-(1,3-Dimethylpyrazol-4-Yl)-1-(3-Fluoro-5-Methoxypyridin-4-Yl)-7-Methoxy-3-Methylimidazo[4,5-C]Quinolin-2-One
    • Niraparib Tosilate Monohydrate
    Belgium Denmark France Germany Italy The Netherlands +2

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Anastrozole
    • Triptorelin
    • Camizestrant
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Gsk4381562A
    • Dostarlimab
    • Gsk6097608
    Denmark Finland France Germany Greece Hungary +6

  • Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Rocatinlimab
    Austria Belgium Bulgaria France Germany Greece +8

  • Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Zasocitinib
    • Apremilast
    Germany Italy Poland

  • Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Datopotamab Deruxtecan
    • Durvalumab
    Belgium Denmark France Germany Greece Italy +2
Previous Page
1 … 36 37 38 39 40 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!